

Aviso de Derechos para emisoras del

FECHA: 09/02/2026



BOLSA MEXICANA DE VALORES, S.A.B DE C.V, INFORMA:

FOLIO DE REFERENCIA DEL EVENTO CORPORATIVO	283830
FOLIO DE REFERENCIA INDEVAL	885374C001
TIPO DE MENSAJE	NEW
COMPLETO / INCOMPLETO	INCOMPLETE
CONFIRMADO / NO CONFIRMADO	UNCONFIRMED

CLAVE DE COTIZACIÓN	BDX
RAZÓN SOCIAL	BECTON, DICKINSON AND COMPANY
SERIE	*
ISIN	US0758871091
MERCADO PRINCIPAL	NEW YORK STOCK EXCHANGE

TIPO DE EVENTO	MERGER
-----------------------	--------

MANDATORIO / OPCIONAL / VOLUNTARIO	Mandatory
---	-----------

OPCIÓN	1
TIPO	Security
DEFAULT	true

TRANSACCIÓN	Securities Movement
CREDIT / DEBIT	Debit

Aviso de Derechos para emisoras del



FECHA: 09/02/2026

VALORES A RECIBIR	
	US0758871091
TRANSACCIÓN	Securities Movement
CREDIT / DEBIT	Credit

RATIO	NewToOld
	0.135 / 1
VALORES A RECIBIR	
	US9418481035
DISPOSICIÓN FRACCIONES	CashInLieuOfFraction

NOTAS DEL EVENTO CORPORATIVO

NOTA
<p>09/02/2026</p> <p>USNW WATERS CORP Symbol WAT Recent Sedar+ Documents BD Completes Combination of Biosciences andamp Diagnostic Solutions Business with Waters Corporation 2026.02.09 08.40 ET . News Release BD Completes Combination of Biosciences and Diagnostic Solutions Business with Waters Corporation PR Newswire FRANKLIN LAKES, N.J., Feb. 9, 2026 FRANKLIN LAKES, N.J., Feb. 9, 2026 PR Newswire BD (Becton, Dickinson and Company) (NYSE: BDX) today announced the successful completion of the previously announced spin-off of BD s Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation (NYSE: WAT). In connection with the transaction, BD shareholders will receive approximately 0.135 shares of Waters common stock for each share of BD common stock that they held as of the close of business on February 5, 2026, the record date for the spin-off, with cash in lieu of any fractional shares of Waters common stock, and BD received USD4 billion of cash. As of the closing of the transaction, BD s shareholders owned shares of Waters common stock representing 39.2 PCT of the outstanding shares of the combined company on a fully diluted basis. Based on the closing price of Waters common stock on February 6, 2026, the transaction valued the BD Biosciences and Diagnostic Solutions business at USD18.8 billion. BD expects to use USD2 billion of the proceeds to repurchase BD common shares through an accelerated share repurchase program and the remaining USD2 billion for debt repayment. Both initiatives are expected to be executed in the near term, subject to market conditions. The successful combination of our Biosciences and Diagnostic Solutions business with Waters marks the final milestone of our BD 2025 strategy, positioning BD for its next chapter as a focused, pure-play MedTech company built for the next era of healthcare. Over the last several years, we have deliberately shaped our portfolio . including divesting three substantial non-core assets and completing more than 20 strategic tuck-in acquisitions . to strengthen our presence in some of the most attractive areas in healthcare. As a result, BD is uniquely positioned to capitalize on the trends we ve identified as shaping the future of healthcare: the rise of smarter connected devices and AI the shift of care to more convenient settings and rapid advances in technologies for chronic disease, said Tom Polen, Chairman, CEO, and President of BD. Looking ahead, BD is accelerating execution through our Excellence Unleashed strategy . strengthening our commercial engine, leading with differentiated innovation, and delivering with exceptional quality and world-class operations. Combined with our global scale, leading positions in the majority of markets we serve, and highly recurring consumables model, we believe BD is well-positioned to generate durable revenue, margin, and cash flow growth to drive shareholder value, Polen added. BD also reported first-quarter fiscal year 2026 financial results today. Pursuant to the terms of the transaction agreement, Claire M. Fraser, Ph.D., has been appointed to the Waters Corporation Board of Directors effective upon the closing of the transaction, and is simultaneously stepping down from the BD Board of Directors, following nearly two decades of dedicated service. Polen concluded, On behalf of the BD Board and management team, we thank Claire for her invaluable contributions to BD. Claire s leadership and expertise in genomics, infectious diseases and molecular diagnostics have been instrumental in guiding our company through transformative periods and shaping the strategic direction of BD. She will provide significant expertise to Waters as part of their Board, and we wish her continued success. Citi served as lead financial advisor to BD, and Evercore also served as a financial advisor. Wachtell, Lipton, Rosen and Katz served as lead legal counsel to BD.</p>